Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JSMO Aims at Health Insurance Coverage of KRAS Gene Testing
April 6, 2009
- Many Patients Hesitate to Request Generic Substitution
April 6, 2009
- Synergism with Millennium to Drive Takeda's Business in Oncology
April 6, 2009
- 12 Drugs and 5 APIs Priced
April 6, 2009
- Falsification of Data Found on World's 1st Recombinant Human Albumin
April 6, 2009
- REGULATORY NEWS IN BRIEF
April 6, 2009
- LDP's Research Commission Calls For More Investment in Pharma R&D
April 6, 2009
- UGT1A1 Gene Polymorphism Testing Reagent from Sekisui Medical
April 6, 2009
- R&D NEWS IN BRIEF
April 6, 2009
- Meiji Seika Licenses Drug for Schizophrenia from ACADIA
April 6, 2009
- 7th JSMO Annual Meeting
April 6, 2009
- Eli Lilly Japan: Sales Up 2% to ¥91,773 Mil.
April 6, 2009
- Aggregates Not Visible with Naked Eye Detected in Kenacort
April 6, 2009
- Mr Matsutani to Step Down as FJPWA President
April 6, 2009
- Pfizer Announces Results of EPPV on Sutent
April 6, 2009
- NEW PRODUCTS
April 6, 2009
- Greater Hypotensive Effects Can Be Expected with Co-DIO: Dr Ogihara
April 6, 2009
- BUSINESS NEWS IN BRIEF
April 6, 2009
- Selective a1-Inhibitors Effective against MS-Associated Dysuria: Prof. Horie
April 6, 2009
- Market Growth for Generics Slowed Down in 4th Qtr of 2008
April 6, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…